The four commonest mutations account for 80% of all KRAS nucleotide changes found in human cancers (85% of all changes in NSCLC), while the nine commonest mutations account for 95% of all changes and 97.5% of changes in NSCLC. Here, KRAS is linked to non-small cell lung carcinoma.